ClinicalTrials.gg
CompletedNCT04254913Updated Jul 16, 2026Results posted

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

A Phase 1 interventional study of MT-1186 in Japanese Patients With ALS, sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shionogi · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Study summary

To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Amyotrophic Lateral Sclerosis Patients with gastrostomy

02

Conditions studied

  • Japanese Patients With ALS
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key criteria are listed below.

  • Patients aged between 20 and 80 years at the time of
  • Japanese patients
  • Among patients with ALS, those "Clinically definite ALS," "Clinically probable ALS" or "Clinically probable-laboratory-supported ALS" according to El Escorial Revised Airlie House criteria
  • ALS Patients with gastrostomy
  • Patients who can consent to
  • Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

The key criteria are listed below.

  • Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy
  • Patients undergoing treatment for .
  • Patients who have presence of liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator
  • (BMI) of \<15.0 or >30.0, or a body weight of \<40 kg
  • Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    MT-1186

    Patients receive the edaravone oral suspension.

    Drug: MT-1186

Interventions

  • Suspension

    Also known as: Edaravone

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  2. Maximum Plasma Concentration (Cmax) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  3. Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  4. Terminal Elimination Half-life (t1/2) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  5. Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  6. Mean Residence Time (MRT) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  7. Apparent Total Clearance (CL/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  8. Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.

  9. Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone

    Time frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration

  10. Cumulative Amount of Drug Excreted in Urine (Ae) of Edaravone

    This information will not be disclosed because it may identify the patient (N=1).

    Time frame: Urine samples are collected: 0 to 8 hours after oral administration

  11. Cumulative Percentage of Drug Excreted in Urine (Ae) of Edaravone

    This information will not be disclosed because it may identify the patient (N=1)

    Time frame: Urine samples are collected: 0 to 8 hours after oral administration

  12. Renal Clearance (CLr) of Edaravone

    This information will not be disclosed because it may identify the patient (N=1).

    Time frame: Urine samples are collected: 0 to 8 hours after oral administration

Secondary outcomes

  1. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: The provision of informed consent to Day 8

07

Results

Posted Jan 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneMT-1186
Started6
Completed5
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · ng·h/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone
ng·h/mLMT-1186
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone2300 ± 950
PrimaryMaximum Plasma Concentration (Cmax) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone
ng/mLMT-1186
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone2163 ± 902.2
PrimaryTime to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Median · h
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
hMT-1186
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone0.29 (0.25 to 0.50)
PrimaryTerminal Elimination Half-life (t1/2) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone
hMT-1186
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone4.47 ± 0.45
PrimaryApparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · 1/h
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone
1/hMT-1186
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone0.1561 ± 0.0138
PrimaryMean Residence Time (MRT) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · h
Mean Residence Time (MRT) of Unchanged Edaravone
hMT-1186
Mean Residence Time (MRT) of Unchanged Edaravone1.89 ± 0.205
PrimaryApparent Total Clearance (CL/F) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · L/h
Apparent Total Clearance (CL/F) of Unchanged Edaravone
L/hMT-1186
Apparent Total Clearance (CL/F) of Unchanged Edaravone54.4 ± 28.1
PrimaryApparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
Reported as:
Mean · L
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
LMT-1186
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone365 ± 236
PrimaryApparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time frame:
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration
Reported as:
Mean · L
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
LMT-1186
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone101 ± 48.1
PrimaryCumulative Amount of Drug Excreted in Urine (Ae) of Edaravone

This information will not be disclosed because it may identify the patient (N=1).

Time frame:
Urine samples are collected: 0 to 8 hours after oral administration
Reported as:
Mean · mg
Cumulative Amount of Drug Excreted in Urine (Ae) of Edaravone
mgMT-1186
Cumulative Amount of Drug Excreted in Urine (Ae) of EdaravoneNA ± NA
PrimaryCumulative Percentage of Drug Excreted in Urine (Ae) of Edaravone

This information will not be disclosed because it may identify the patient (N=1)

Time frame:
Urine samples are collected: 0 to 8 hours after oral administration
Reported as:
Mean · percentage of dose
Cumulative Percentage of Drug Excreted in Urine (Ae) of Edaravone
percentage of doseMT-1186
Cumulative Percentage of Drug Excreted in Urine (Ae) of EdaravoneNA ± NA
PrimaryRenal Clearance (CLr) of Edaravone

This information will not be disclosed because it may identify the patient (N=1).

Time frame:
Urine samples are collected: 0 to 8 hours after oral administration
Reported as:
Mean · L/h
Renal Clearance (CLr) of Edaravone
L/hMT-1186
Renal Clearance (CLr) of EdaravoneNA ± NA
SecondaryNumber of Participants With Adverse Events and Adverse Drug Reactions
Time frame:
The provision of informed consent to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Adverse Drug Reactions
ParticipantsMT-1186
Number of Participants with Adverse events3
Number of Participants with adverse drug reactions0

Adverse events

Collected over The provision of informed consent to Day 8. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-11860/6 (0%)2/6 (33.3%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventMT-1186
Tibia fractureInjury, poisoning and procedural complications1/6
Spinal compression fractureInjury, poisoning and procedural complications1/6
Respiratory disorderRespiratory, thoracic and mediastinal disorders1/6
Most frequent other events
Most frequent other events
EventMT-1186
FolliculitisInfections and infestations1/6
Urinary tract infectionInfections and infestations1/6
Anal eczemaGastrointestinal disorders1/6
Stoma site hypergranulationInjury, poisoning and procedural complications1/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MT-1186
<=18 years0
Between 18 and 65 years2
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)MT-1186
Female3
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MT-1186
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Investigational site
    Chiba, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Yashiro M, Ueda M, Hirai M, Yoshino H, Mizutani T, Kanai K, Kano O, Kimura H, Sekino H, Ito K. Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clin Ther. 2023 Dec;45(12):1251-1258. doi: 10.1016/j.clinthera.2023.09.025. Epub 2023 Nov 11. PubMed 37953075 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Apr 2020, 2 months.

Results were first posted in Jan 2024, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2020
First posted
Feb 5, 2020
StartActual
Jan 24, 2020
Primary completionActual
Apr 16, 2020
CompletionActual
Apr 22, 2020
Results first posted
Jan 24, 2024
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04254913
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Feb 5, 2020
Start date
Jan 24, 2020
Primary completion
Apr 16, 2020
Completion
Apr 22, 2020
Results posted
Jan 24, 2024
Last update
Jul 16, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion